循環器ジャーナル68巻4号

2020年10月発行

特集 抗血栓療法—日常臨床での疑問に応える Ⅰ．心房細動に対する抗血栓療法

除細動時の抗凝固療法の注意点は？

著者： 是恒之宏¹

所属機関： ¹国立病院機構大阪医療センター

ページ範囲：P.608 - P.610

Point
・緊急性が高い場合を除いて，48時間以上続く心房細動の除細動前3週間と，除細動後4週間の抗凝固療法は必須である．
・除細動前，新たに抗凝固薬を開始する場合，ワルファリンは維持量到達後の3週間であり実際にはより長期間を要する．
・経食道エコーで左房内血栓がないことを確認できればヘパリン投与後に除細動することが可能である．

参考文献

1) Brunetti ND, Tarantino N, Gennaro LD, et al:Direct Oral Anti-Coagulants Compared to vitamin-K Antagonists in Cardioversion of Atrial Fibrillation:An Updated Meta-Analysis. J Thromb Thrombolysis 45:550-556, 2018

2) Arnold AZ, Mick MJ, Mazurek RP, et al:Role of Prophylactic Anticoagulation for Direct Current Cardioversion in Patients With Atrial Fibrillation or Atrial Flutter. J Am Coll Cardiol 19:851-855, 1992

3) Naccarelli GV, Dell'Orfano JT, Wolbrette DL, et al:Cost-effective Management of Acute Atrial Fibrillation:Role of Rate Control, Spontaneous Conversion, Medical and Direct Current Cardioversion, Transesophageal Echocardiography, and Antiembolic Therapy. Am J Cardiol 85:36D-45D, 2000

4) Prystowsky EN, Benson W Jr, Fuster V, et al:Management of Patients With Atrial Fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation 93:1262-1277, 1996

5) Hart RG, Halperin JL:Atrial Fibrillation and Thromboembolism:A Decade of Progress in Stroke Prevention. Ann Intern Med 131:688-695, 1999

6) Mancini GB, Goldberger AL:Cardioversion of Atrial Fibrillation:Consideration of Embolization, Anticoagulation, Prophylactic Pacemaker, and Long-Term Success. Am Heart J 104:617-621, 1982

7) Nagarakanti R, Ezekowitz MD, Oldgren J, et al:Dabigatran Versus Warfarin in Patients With Atrial Fibrillation:An Analysis of Patients Undergoing Cardioversion. Circulation 123:131-136, 2011

8) Flaker G, Lopes RD, Al-Khatib SM, et al:Efficacy and Safety of Apixaban in Patients After Cardioversion for Atrial Fibrillation:Insights From the ARISTOTLE Trial. J Am Coll Cardiol 63:1082-1087, 2014

9) Plitt A, Ezekowitz MD, De Caterina R, et al:Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48 Clin Cardiol 39:345-346, 2016

10) Pallisgaard JL, Lindhardt TB, Hansen ML, et al:Cardioversion and Risk of Adverse Events With Dabigatran Versus Warfarin-A Nationwide Cohort Study. PLoS One 10:e0141377, 2015

11) Ezekowitz MD, Pollack CV, Halperin JL, et al:Apixaban Compared to Heparin/Vitamin K Antagonist in Patients With Atrial Fibrillation Scheduled for Cardioversion:The EMANATE Trial. Eur Heart J 39:2959-2971, 2018

12) Cappato R, Ezekowitz MD, Klein AL, et al:Rivaroxaban vs. Vitamin K Antagonists for Cardioversion in Atrial Fibrillation. Eur Heart J 35:3346-3355, 2014

13) Camm AJ, Turpie AGG, Hess S, et al:Outcomes After Catheter Ablation and Cardioversion in Patients With Non-Valvular Atrial Fibrillation:Results From the Prospective, Observational XANTUS Study. Europace 20:e87-e95, 2018

14) Goette A, Merino JL, Ezekowitz MD, et al:Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation（ENSURE-AF）:A Randomised, Open-Label, Phase 3b Trial. Lancet 388:1995-2003, 2016

15) Renda G, Ricci F, Caterina RD:Non-Vitamin K Antagonist Oral Anticoagulants for Cardioversion in Atrial Fibrillation:An Updated Meta-analysis. Am J Med 130:457-461, 2017

16) Gibson CM, Basto AN, Howard ML:Direct Oral Anticoagulants in Cardioversion:A Review of Current Evidence. Ann Pharmacother 52:277-284, 2018

17) Telles-Garcia N, Dahal K, Kocherla C, et al:Non-vitamin K Antagonists Oral Anticoagulants Are as Safe and Effective as Warfarin for Cardioversion of Atrial Fibrillation:A Systematic Review and Meta-Analysis. Int J Cardiol 268:143-148, 2018

18) Fatkin D, Kuchar DL, Thorburn CW, et al:Transesophageal Echocardiography Before and During Direct Current Cardioversion of Atrial Fibrillation:Evidence for “Atrial Stunning” as a Mechanism of Thromboembolic Complications. J Am Coll Cardiol 23:307-316, 1994

19) Berger M, Schweitzer P:Timing of Thromboembolic Events After Electrical Cardioversion of Atrial Fibrillation or Flutter:A Retrospective Analysis. Am J Cardiol 82:1545-1547, 1998

20) Klein AL, Grimm RA, Murray RD, et al:Use of Transesophageal Echocardiography to Guide Cardioversion in Patients With Atrial Fibrillation. N Engl J Med 344:1411-1420, 2001

21) Mehta D, Baruch L:Thromboembolism Following Cardioversion of “Common” Atrial Flutter. Risk Factors and Limitations of Transesophageal Echocardiography. Chest 110:1001-1003, 1996

22) Irani WN, Grayburn PA, Afridi I:Prevalence of Thrombus, Spontaneous Echo Contrast, and Atrial Stunning in Patients Undergoing Cardioversion of Atrial Flutter. A Prospective Study Using Transesophageal Echocardiography. Circulation 95:962-966, 1997